On the public citation graph
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
0 signed · 1339 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2014.11061openalex-snapshot
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
inferredcites →https://doi.org/10.1001/jama.2016.3609openalex-snapshot
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction
inferredcites →https://doi.org/10.1002/art.23721openalex-snapshot
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
inferredcites →https://doi.org/10.1002/sim.1296openalex-snapshot
Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems
inferredcites →https://doi.org/10.1007/978-1-4612-4380-9_25openalex-snapshot
Nonparametric Estimation from Incomplete Observations
inferredcites →https://doi.org/10.1016/j.ahj.2013.03.018openalex-snapshot
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
inferredcites →https://doi.org/10.1016/j.amjcard.2011.06.054openalex-snapshot
Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
inferredcites →https://doi.org/10.1016/j.jacc.2009.09.009openalex-snapshot
Inflammation in Atherosclerosis
inferredcites →https://doi.org/10.1016/j.semarthrit.2013.08.003openalex-snapshot
Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs
inferredcites →https://doi.org/10.1016/s0140-6736(02)08213-2openalex-snapshot
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
inferredcites →https://doi.org/10.1016/s0140-6736(17)32814-3openalex-snapshot
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
inferredcites →https://doi.org/10.1016/s0197-2456(00)00057-xopenalex-snapshot
Computations for Group Sequential Boundaries Using the Lan-DeMets Spending Function Method
inferredcites →https://doi.org/10.1023/a:1025822717910openalex-snapshot
Adaptive test for testing the difference in survival distributions.
inferredcites →https://doi.org/10.1038/nrcardio.2017.161openalex-snapshot
The NLRP3 inflammasome in acute myocardial infarction
inferredcites →https://doi.org/10.1038/nrrheum.2010.5openalex-snapshot
Methotrexate—how does it really work?
inferredcites →https://doi.org/10.1056/nejm198503283121303openalex-snapshot
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejm199204163261602openalex-snapshot
Methotrexate in Resistant Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejmoa1107579openalex-snapshot
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
inferredcites →https://doi.org/10.1056/nejmoa1707914openalex-snapshot
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
inferredcites →https://doi.org/10.1056/nejmra043430openalex-snapshot
Inflammation, Atherosclerosis, and Coronary Artery Disease
inferredcites →https://doi.org/10.1093/aje/kwi309openalex-snapshot
Comparison of Risk Factors for the Competing Risks of Coronary Heart Disease, Stroke, and Venous Thromboembolism
inferredcites →https://doi.org/10.1093/biomet/68.1.316openalex-snapshot
The Asymptotic Properties of Nonparametric Tests for Comparing Survival Distributions
inferredcites →https://doi.org/10.1093/eurheartj/ehw024openalex-snapshot
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
inferredcites →https://doi.org/10.1093/eurheartj/ehy310openalex-snapshot
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
inferredcites →https://doi.org/10.1093/rheumatology/kep366openalex-snapshot
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
inferredcites →https://doi.org/10.1093/rheumatology/kew214openalex-snapshot
Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study
inferredcites →https://doi.org/10.1136/bmj.319.7223.1492openalex-snapshot
Calculating the number needed to treat for trials where the outcome is time to an event
inferredcites →https://doi.org/10.1161/circresaha.115.306656openalex-snapshot
From C-Reactive Protein to Interleukin-6 to Interleukin-1
inferredcites →https://doi.org/10.1161/circresaha.117.311984openalex-snapshot
CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis
inferredcites →https://doi.org/10.1172/jci116884openalex-snapshot
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.
inferredcites →https://doi.org/10.1186/1471-2474-12-153openalex-snapshot
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
inferredcites →https://doi.org/10.2307/2531201openalex-snapshot
Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
inferredcites →https://doi.org/10.2307/2532940openalex-snapshot
Applying Cox Regression to Competing Risks
inferredcites →https://doi.org/10.3899/jrheum.100041openalex-snapshot
Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5116096openalex-extracted
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence Mapping
inferred← citeshttps://doi.org/10.1001/jama.2022.9165openalex-snapshot
Cardiovascular Events and Gout Flares
inferred← citeshttps://doi.org/10.1001/jamacardio.2018.4566openalex-snapshot
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
inferred← citeshttps://doi.org/10.1001/jamacardio.2020.2413openalex-snapshot
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease
inferred← citeshttps://doi.org/10.1001/jamacardio.2020.5392openalex-snapshot
Association of Circulating Monocyte Chemoattractant Protein–1 Levels With Cardiovascular Mortality
inferred← citeshttps://doi.org/10.1001/jamacardio.2021.3079openalex-snapshot
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome
inferred← citeshttps://doi.org/10.1001/jamacardio.2024.2859openalex-snapshot
Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis
inferred← citeshttps://doi.org/10.1001/jamainternmed.2021.5726openalex-snapshot
Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.45132openalex-snapshot
Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1002/14651858.cd012825.pub2openalex-snapshot
Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack
inferred← citeshttps://doi.org/10.1002/14651858.cd014808.pub2openalex-snapshot
Colchicine for the secondary prevention of cardiovascular events
inferred← citeshttps://doi.org/10.1002/9781119603207.ch19openalex-snapshot
Treatment Strategies in Patients with Diabetes Mellitus and Ischemic Heart Disease
inferred← citeshttps://doi.org/10.1002/9781119697367.ch1openalex-snapshot
Atherogenesis and Inflammation
inferred← citeshttps://doi.org/10.1002/9781119697367.ch44openalex-snapshot
Secondary Prevention of Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1002/acr2.1001openalex-snapshot
Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1002/acr2.11187openalex-snapshot
Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial
inferred← citeshttps://doi.org/10.1002/acr2.11256openalex-snapshot
Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
inferred← citeshttps://doi.org/10.1002/acr2.11432openalex-snapshot
Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk
inferred← citeshttps://doi.org/10.1002/acr2.90050openalex-snapshot
Immunosuppressive Medications and Nonserious Infections in People With Rheumatoid Arthritis: A Prospective Cohort Study
inferred← citeshttps://doi.org/10.1002/advs.202501820openalex-snapshot
Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms
inferred← citeshttps://doi.org/10.1002/advs.202504990openalex-snapshot
Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization
inferred← citeshttps://doi.org/10.1002/advs.77260openalex-snapshot
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
inferred← citeshttps://doi.org/10.1002/art.41092openalex-snapshot
When Randomized Clinical Trials and Real‐World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety
inferred← citeshttps://doi.org/10.1002/art.41384openalex-snapshot
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial
inferred← citeshttps://doi.org/10.1002/art.41452openalex-snapshot
Pulmonary Adverse Events in Patients Receiving Low‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction Trial
inferred← citeshttps://doi.org/10.1002/art.41589openalex-snapshot
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
inferred← citeshttps://doi.org/10.1002/ccd.28784openalex-snapshot
Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single‐center registry
inferred← citeshttps://doi.org/10.1002/ccd.29402openalex-snapshot
Prevalence and prognostic impact of hsCRP elevation are age‐dependent in women but not in men undergoing percutaneous coronary intervention
inferred← citeshttps://doi.org/10.1002/ccd.29870openalex-snapshot
Long‐term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention
inferred← citeshttps://doi.org/10.1002/cpt.1637openalex-snapshot
The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure
inferred← citeshttps://doi.org/10.1002/cpt.2858openalex-snapshot
Genome‐wide Association Study of Methotrexate‐Induced Liver Injury in Rheumatoid Arthritis Patients
inferred← citeshttps://doi.org/10.1002/ctd2.70064openalex-snapshot
Therapeutic potential of the annexin A family in atherosclerosis
inferred← citeshttps://doi.org/10.1002/ddr.70283openalex-snapshot
Targeting the NLRP3 Inflammasome: Novel Inhibitors for Cardiovascular Diseases Management — A Narrative Review
inferred← citeshttps://doi.org/10.1002/jvc2.70134openalex-snapshot
Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review
inferred← citeshttps://doi.org/10.1002/mco2.70878openalex-snapshot
The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets
inferred← citeshttps://doi.org/10.1002/mdb2.70046openalex-snapshot
Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints
inferred← citeshttps://doi.org/10.1002/mdr2.70064openalex-snapshot
Inflammation, Immunity, and Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1002/mnfr.201900482openalex-snapshot
Metabolic Inflammation in Obesity—At the Crossroads between Fatty Acid and Cholesterol Metabolism
inferred← citeshttps://doi.org/10.1002/mnfr.201900797openalex-snapshot
The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis
inferred← citeshttps://doi.org/10.1002/mnfr.202000097openalex-snapshot
Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?
inferred← citeshttps://doi.org/10.1002/pds.5546openalex-snapshot
Examining the potential direct cardiovascular benefit of tumor‐necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses
inferred← citeshttps://doi.org/10.1002/pds.5716openalex-snapshot
Stratified analysis in comparative effectiveness studies that emulate randomized trials
inferred← citeshttps://doi.org/10.1002/phar.2401openalex-snapshot
Colchicine for Secondary Cardiovascular Prevention: A Systematic Review
inferred← citeshttps://doi.org/10.1007/978-1-0716-1924-7_1openalex-snapshot
Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions
inferred← citeshttps://doi.org/10.1007/978-1-0716-1924-7_2openalex-snapshot
Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation
inferred← citeshttps://doi.org/10.1007/978-3-030-22009-9_819openalex-snapshot
Rheumatic Diseases Among Older Adults
inferred← citeshttps://doi.org/10.1007/978-3-030-40570-0_9openalex-snapshot
Perivascular Adipose Tissue and Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-47336-5_2openalex-snapshot
Obesity-Induced Cardiovascular Complications and Therapeutic Intervention
inferred← citeshttps://doi.org/10.1007/978-3-030-54779-0_22openalex-snapshot
Cardiovascular Side Effects of Medications for Skin Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-56279-3_14openalex-snapshot
Inflammation and Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_30openalex-snapshot
C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_33openalex-snapshot
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-62080-6_13openalex-snapshot
Personalized Therapy of Cardiovascular Disorders
inferred← citeshttps://doi.org/10.1007/978-3-030-89340-8_11openalex-snapshot
Oxidative Stress in Men with Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: Mechanisms and Management of Reproductive Dysfunction
inferred← citeshttps://doi.org/10.1007/978-3-030-98824-1_13openalex-snapshot
Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention
inferred← citeshttps://doi.org/10.1007/978-3-030-98824-1_17openalex-snapshot
High-Sensitivity C-Reactive Protein
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_10openalex-snapshot
The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-17572-5_10openalex-snapshot
Management of Dysregulated Immune Response in the Critically Ill: Heart and Circulation
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_30openalex-snapshot
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-39721-9_7openalex-snapshot
Inflammation and Vascular Pathologies
inferred← citeshttps://doi.org/10.1007/978-3-031-49963-0_11openalex-snapshot
“Management of Emerging or Unconventional Risk Factors”
inferred← citeshttps://doi.org/10.1007/978-3-031-55254-0_24-1openalex-snapshot
The Intersection of Blood Vessel Inflammation in Autoimmune and Metabolic Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-65952-2_14openalex-snapshot
Rheumatic and Autoimmune Disorders and CVD Risk in Women
inferred← citeshttps://doi.org/10.1007/978-3-319-69892-2_819-1openalex-snapshot
Rheumatic Diseases Among Older Adults
inferred← citeshttps://doi.org/10.1007/978-981-15-2517-9_8openalex-snapshot
Drug Discovery for Coronary Artery Disease
inferred← citeshttps://doi.org/10.1007/s00011-020-01382-6openalex-snapshot
The role of interferon-γ in cardiovascular disease: an update
inferred← citeshttps://doi.org/10.1007/s00011-023-01845-6openalex-snapshot
Inflammation in heart failure: pathophysiology and therapeutic strategies
inferred← citeshttps://doi.org/10.1007/s00011-025-02058-9openalex-snapshot
Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials
inferred← citeshttps://doi.org/10.1007/s00059-019-4790-yopenalex-snapshot
Immunität und Entzündung bei Arteriosklerose
inferred← citeshttps://doi.org/10.1007/s00108-022-01416-7openalex-snapshot
Rolle der Metaflammation als systemische Manifestation bei Stoffwechselerkrankungen
inferred← citeshttps://doi.org/10.1007/s00108-026-02096-3openalex-snapshot
Antiinflammatorische Therapiestrategien bei koronarer Herzkrankheit
inferred← citeshttps://doi.org/10.1007/s00204-023-03492-6openalex-snapshot
Understanding the molecular mechanisms of statin pleiotropic effects
inferred← citeshttps://doi.org/10.1007/s00210-024-03330-1openalex-snapshot
Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial
inferred← citeshttps://doi.org/10.1007/s00259-026-07809-2openalex-snapshot
Molecular imaging of lymphatic organs provides prognostic value after acute myocardial infarction
inferred← citeshttps://doi.org/10.1007/s00296-020-04694-2openalex-snapshot
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates
inferred← citeshttps://doi.org/10.1007/s00296-025-05868-6openalex-snapshot
Gout and rheumatoid arthritis are associated with subclinical vascular damage, reduced brachial vasoreactivity and coronary microvascular dysfunction: a case-control study
inferred← citeshttps://doi.org/10.1007/s00296-026-06269-zopenalex-snapshot
Ten-year incidence and heart failure dominance of hospitalized cardiovascular events in rheumatoid arthritis: a hospital-based cohort study from Martinique
inferred← citeshttps://doi.org/10.1007/s00392-019-01511-0openalex-snapshot
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort
inferred← citeshttps://doi.org/10.1007/s00392-021-01828-9openalex-snapshot
Colchicine in ischemic heart disease: the good, the bad and the ugly
inferred← citeshttps://doi.org/10.1007/s00392-023-02254-9openalex-snapshot
A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease
inferred← citeshttps://doi.org/10.1007/s00392-023-02291-4openalex-snapshot
Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00395-020-00838-4openalex-snapshot
Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering
inferred← citeshttps://doi.org/10.1007/s00395-022-00927-6openalex-snapshot
P2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction
inferred← citeshttps://doi.org/10.1007/s00395-025-01121-0openalex-snapshot
Anti-inflammatory interventions in coronary artery disease: antipodal responses requiring targeted therapeutic strategies
inferred← citeshttps://doi.org/10.1007/s10067-021-06003-zopenalex-snapshot
Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1007/s10067-025-07310-5openalex-snapshot
Low prevalence of methotrexate intolerance in rheumatoid arthritis: a South African study
inferred← citeshttps://doi.org/10.1007/s10554-020-02073-3openalex-snapshot
Inflammation as a determinant of healing response after coronary stent implantation
inferred← citeshttps://doi.org/10.1007/s10554-024-03238-0openalex-snapshot
18F-fluorodeoxyglucose PET-MR characterization of aortic inflammation in ApoE−/− mouse models of accelerated atherosclerosis: comparison of Western diet vs. uremia
inferred← citeshttps://doi.org/10.1007/s10557-020-07106-6openalex-snapshot
Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.
inferred← citeshttps://doi.org/10.1007/s10557-021-07239-2openalex-snapshot
Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation
inferred← citeshttps://doi.org/10.1007/s10557-024-07622-9openalex-snapshot
Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1007/s10571-026-01722-wopenalex-snapshot
Mapping the Neurovascular Unit Genetic Architecture of Early-Onset Ischemic Stroke: A Single-Cell Causal Framework for Target Discovery and Therapeutic Translation
inferred← citeshttps://doi.org/10.1007/s10741-019-09860-8openalex-snapshot
Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
inferred← citeshttps://doi.org/10.1007/s10741-025-10519-wopenalex-snapshot
A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure
inferred← citeshttps://doi.org/10.1007/s10741-025-10538-7openalex-snapshot
Targeting inflammation in heart failure: evolving insights and future directions from randomized clinical trials
inferred← citeshttps://doi.org/10.1007/s10787-021-00865-0openalex-snapshot
Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial
inferred← citeshttps://doi.org/10.1007/s11033-021-06483-xopenalex-snapshot
Treg cells in atherosclerosis
inferred← citeshttps://doi.org/10.1007/s11357-022-00556-wopenalex-snapshot
Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11739-020-02606-7openalex-snapshot
Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11845-022-02938-7openalex-snapshot
Colchicine—regeneration of an old drug
inferred← citeshttps://doi.org/10.1007/s11883-020-00883-3openalex-snapshot
Targeting Inflammation to Reduce Residual Cardiovascular Risk
inferred← citeshttps://doi.org/10.1007/s11883-020-00887-zopenalex-snapshot
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
inferred← citeshttps://doi.org/10.1007/s11883-020-00891-3openalex-snapshot
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
inferred← citeshttps://doi.org/10.1007/s11883-020-0822-6openalex-snapshot
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions
inferred← citeshttps://doi.org/10.1007/s11883-021-00932-5openalex-snapshot
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
inferred← citeshttps://doi.org/10.1007/s11883-022-01075-xopenalex-snapshot
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
inferred← citeshttps://doi.org/10.1007/s11883-024-01221-7openalex-snapshot
The Emerging Specialty of Cardio-Rheumatology
inferred← citeshttps://doi.org/10.1007/s11883-024-01225-3openalex-snapshot
Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia
inferred← citeshttps://doi.org/10.1007/s11883-024-01241-3openalex-snapshot
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
inferred← citeshttps://doi.org/10.1007/s11883-024-01263-xopenalex-snapshot
Inflammation in the Peri-ACS Period: Ready for Prime Time?
inferred← citeshttps://doi.org/10.1007/s11883-025-01324-9openalex-snapshot
Anti-Atherogenic Mechanisms and Therapies
inferred← citeshttps://doi.org/10.1007/s11883-025-01357-0openalex-snapshot
Review of OxLDL Driven Inflammatory Cell Activation
inferred← citeshttps://doi.org/10.1007/s11883-026-01394-3openalex-snapshot
From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis
inferred← citeshttps://doi.org/10.1007/s11886-020-01358-2openalex-snapshot
Targeting Inflammation After Myocardial Infarction
inferred← citeshttps://doi.org/10.1007/s11886-020-01372-4openalex-snapshot
Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation
inferred← citeshttps://doi.org/10.1007/s11886-020-01439-2openalex-snapshot
Update on the Inflammatory Hypothesis of Coronary Artery Disease
inferred← citeshttps://doi.org/10.1007/s11886-021-01560-wopenalex-snapshot
Colchicine in the Management of Acute and Chronic Coronary Artery Disease
inferred← citeshttps://doi.org/10.1007/s11886-024-02026-5openalex-snapshot
Update on the Role of Colchicine in Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s11886-024-02049-yopenalex-snapshot
Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
inferred← citeshttps://doi.org/10.1007/s11892-022-01451-6openalex-snapshot
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
inferred← citeshttps://doi.org/10.1007/s11897-024-00682-wopenalex-snapshot
Heart Failure in Rheumatoid Arthritis: Clinical Implications
inferred← citeshttps://doi.org/10.1007/s11936-019-0741-4openalex-snapshot
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1007/s11936-023-01024-0openalex-snapshot
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
inferred← citeshttps://doi.org/10.1007/s11936-025-01130-1openalex-snapshot
Treating Inflammation for Cardiovascular Prevention
inferred← citeshttps://doi.org/10.1007/s12026-026-09784-0openalex-snapshot
Crosstalk between the monocytes and coagulation factor VⅡa aggravates the inflammation in patients with CAD
inferred← citeshttps://doi.org/10.1007/s12035-024-04411-1openalex-snapshot
Plasma Proteomes and Genome-Wide Association Data for Causal Protein Identification in Stroke
inferred← citeshttps://doi.org/10.1007/s12170-019-0606-0openalex-snapshot
Evaluation and Management of the Vulnerable Plaque
inferred← citeshttps://doi.org/10.1007/s12247-024-09818-wopenalex-snapshot
Repurposing of IL 33/ST2 Modulating Drugs as a Cardioprotective Agent: A Promising Approach
inferred← citeshttps://doi.org/10.1007/s12265-020-09961-yopenalex-snapshot
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
inferred← citeshttps://doi.org/10.1007/s12265-020-09974-7openalex-snapshot
Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model
inferred← citeshttps://doi.org/10.1007/s12265-020-09994-3openalex-snapshot
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s12265-020-10000-zopenalex-snapshot
Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation
inferred← citeshttps://doi.org/10.1007/s12265-020-10025-4openalex-snapshot
A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy
inferred← citeshttps://doi.org/10.1007/s12265-020-10026-3openalex-snapshot
Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s12325-019-00962-1openalex-snapshot
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12471-021-01599-yopenalex-snapshot
The challenge of choosing in cardiovascular risk management
inferred← citeshttps://doi.org/10.1007/s12471-021-01605-3openalex-snapshot
Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail
inferred← citeshttps://doi.org/10.1007/s13555-022-00790-2openalex-snapshot
Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s15006-019-1214-0openalex-snapshot
Colchicin reduziert ischämische Komplikationen nach Herzinfarkt
inferred← citeshttps://doi.org/10.1007/s15006-021-0283-zopenalex-snapshot
Der kardiovaskulär vorerkrankte Diabetespatient
inferred← citeshttps://doi.org/10.1007/s15027-019-1539-8openalex-snapshot
Inflammation als therapeutisches Target
inferred← citeshttps://doi.org/10.1007/s15027-019-1654-6openalex-snapshot
Colchicin reduziert ischämische Komplikationen nach Herzinfarkt
inferred← citeshttps://doi.org/10.1007/s40119-024-00376-3openalex-snapshot
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s40256-018-00315-3openalex-snapshot
How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
inferred← citeshttps://doi.org/10.1007/s40256-019-00376-yopenalex-snapshot
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease
inferred← citeshttps://doi.org/10.1007/s40256-021-00485-7openalex-snapshot
Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s40261-021-01056-zopenalex-snapshot
Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials
inferred← citeshttps://doi.org/10.1007/s40266-019-00653-0openalex-snapshot
Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
inferred← citeshttps://doi.org/10.1007/s40266-024-01175-0openalex-snapshot
Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People
inferred← citeshttps://doi.org/10.1007/s40292-021-00493-3openalex-snapshot
Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk
inferred← citeshttps://doi.org/10.1007/s40744-021-00397-7openalex-snapshot
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice
inferred← citeshttps://doi.org/10.1007/s40744-023-00546-0openalex-snapshot
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
inferred← citeshttps://doi.org/10.1007/s40744-024-00721-xopenalex-snapshot
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
inferred← citeshttps://doi.org/10.1016/b978-0-12-814551-7.00036-2openalex-snapshot
Mechanisms of vascular damage in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1016/b978-0-12-814551-7.00044-1openalex-snapshot
Cardiovascular disease in systemic lupus erythematosus: an update
inferred← citeshttps://doi.org/10.1016/b978-0-12-824390-9.00009-8openalex-snapshot
Precision medicine to manage chronic immune-related conditions
inferred← citeshttps://doi.org/10.1016/b978-0-323-87862-3.00007-0openalex-snapshot
Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-323-88286-6.00008-xopenalex-snapshot
High-Sensitivity C-Reactive Protein
inferred← citeshttps://doi.org/10.1016/b978-0-323-88286-6.00013-3openalex-snapshot
Treatment Guidelines Overview
inferred← citeshttps://doi.org/10.1016/b978-0-323-88286-6.00024-8openalex-snapshot
Anti-inflammatory Therapy for Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/b978-0-323-99988-5.00005-xopenalex-snapshot
Advanced therapeutics for targeting atherosclerosis
inferred← citeshttps://doi.org/10.1016/b978-0-443-15512-3.00012-xopenalex-snapshot
Chronic Inflammation in Atherosclerosis and Arteriosclerosis
inferred← citeshttps://doi.org/10.1016/b978-0-443-23722-5.00005-4openalex-snapshot
Metabolic syndrome and psoriatic arthritis
inferred← citeshttps://doi.org/10.1016/b978-0-443-23722-5.00009-1openalex-snapshot
Infection and rheumatoid arthritis, spondyloarthritis and psoriatic arthritis
inferred← citeshttps://doi.org/10.1016/b978-0-443-23722-5.00013-3openalex-snapshot
Cardiovascular disease and rheumatoid arthritis
inferred← citeshttps://doi.org/10.1016/b978-0-443-33957-8.00045-7openalex-snapshot
Cardiovascular disease in systemic lupus erythematosus: An update
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2024.02.001openalex-snapshot
Drug repurposing: A multi targetted approach to treat cardiac disease from existing classical drugs to modern drug discovery
inferred← citeshttps://doi.org/10.1016/j.actbio.2022.12.007openalex-snapshot
Inflammation specific environment activated methotrexate-loaded nanomedicine to treat rheumatoid arthritis by immune environment reconstruction
inferred← citeshttps://doi.org/10.1016/j.addr.2020.07.011openalex-snapshot
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
inferred← citeshttps://doi.org/10.1016/j.ahj.2019.06.003openalex-snapshot
The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction
inferred← citeshttps://doi.org/10.1016/j.ahj.2019.08.003openalex-snapshot
C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort
inferred← citeshttps://doi.org/10.1016/j.ahj.2022.06.004openalex-snapshot
Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography
inferred← citeshttps://doi.org/10.1016/j.ahj.2024.08.022openalex-snapshot
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial
inferred← citeshttps://doi.org/10.1016/j.ahjo.2021.100057openalex-snapshot
Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?
inferred← citeshttps://doi.org/10.1016/j.ahjo.2023.100257openalex-snapshot
Small vessel disease: Connections between the kidney and the heart
inferred← citeshttps://doi.org/10.1016/j.ahjo.2023.100267openalex-snapshot
Chronic rheumatologic disorders and cardiovascular disease risk in women
inferred← citeshttps://doi.org/10.1016/j.ajpc.2020.100027openalex-snapshot
Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease’s ‘ABC’s Approach
inferred← citeshttps://doi.org/10.1016/j.ajpc.2022.100373openalex-snapshot
GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis
inferred← citeshttps://doi.org/10.1016/j.ajpc.2026.101642openalex-snapshot
Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials
inferred← citeshttps://doi.org/10.1016/j.ajpc.2026.101799openalex-snapshot
Preparing for the full ZEUS results and the unfinished question of IL-6 inhibition
inferred← citeshttps://doi.org/10.1016/j.ajpc.2026.101808openalex-snapshot
Healthcare professional awareness and use of inflammation-based risk assessment in ASCVD: The CARDIO-INFLAME survey
inferred← citeshttps://doi.org/10.1016/j.ajpc.2026.101817openalex-snapshot
Inflammation and ASCVD: sound biology, unfinished therapeutics, and lessons from CARDIO-INFLAME
inferred← citeshttps://doi.org/10.1016/j.amjcard.2020.10.043openalex-snapshot
Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease
inferred← citeshttps://doi.org/10.1016/j.amjcard.2021.12.042openalex-snapshot
Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris
inferred← citeshttps://doi.org/10.1016/j.amjcard.2025.08.013openalex-snapshot
Systemic Review of Inflammatory Pathways and Immune Modulation in Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/j.amjcard.2026.03.058openalex-snapshot
Beyond Percutaneous Coronary Intervention - Targeted Molecular Therapies for the Next Era of Coronary Care
inferred← citeshttps://doi.org/10.1016/j.amjmed.2019.05.021openalex-snapshot
Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction
inferred← citeshttps://doi.org/10.1016/j.anai.2023.11.009openalex-snapshot
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
inferred← citeshttps://doi.org/10.1016/j.arr.2025.102695openalex-snapshot
Adenosine metabolism and receptors in aging of the skin, musculoskeletal, immune and cardiovascular systems
inferred← citeshttps://doi.org/10.1016/j.arr.2025.102757openalex-snapshot
Intercellular communication after myocardial infarction: Macrophage as the centerpiece
inferred← citeshttps://doi.org/10.1016/j.artere.2020.03.006openalex-snapshot
Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study
inferred← citeshttps://doi.org/10.1016/j.arteri.2020.03.002openalex-snapshot
Efecto del clopidogrel vs. aspirina en la función de la expresión del inflamasoma proaterosclerótico NLRP1 en células endoteliales. Estudio ECLOAS
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2019.08.014openalex-snapshot
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2020.03.022openalex-snapshot
The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2020.05.018openalex-snapshot
Platelets as therapeutic targets to prevent atherosclerosis
showing the first 200 of 1303 · page through all 1303
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.